Jasmeet C. Singh, MD, discusses the future of the treatment landscape for HER2-positive breast cancer following positive new research presented at the 2019 San Antonio Breast Cancer Symposium.
Videos
Michael Wang, MD, discusses the approaches physicians can use when treating their patients with mantle cell lymphoma who have become resistant to cellular therapies, such as CAR T-cell therapy.
Ruben Mesa, MD, discusses the current state of the treatment landscape for patients with myeloproliferative neoplasms.
Joseph Chao, MD, discusses the importance of assessing the microsatellite instability (MSI) status in patients with advanced gastric/gastroesophageal junction cancer based on findings from a comparative analysis of KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
2
ctDNA Refines Risk in Neoadjuvant-Resistant Breast Cancer
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
High Survival Seen with Nogapendekin Alfa Inbakicept in Papillary NMIBC
5